Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma

Summary

This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment. It is a single arm, open-label clinical trial conducted in China, and plan to recruit 28 patients. Primary endpoint of the study is Progress Free Survival.

Timeline

Start

2019-09-24

Primary completion

2021-02

Completion

2021-10

Drugs

Indications